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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effectiveness of oral, inhaled or intranasal aspirin desensitisation, as monotherapy or as adjunctive therapy, in adult patients
with aspirin intolerant chronic rhinosinusitis, with or without concomitant asthma.Wewill evaluate subjective and objective parameters
of nasal and lower airway function, quality of life and adverse event profiles.
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B A C K G R O U N D
Chronic rhinosinusitis is a common respiratory disorder involv-
ing inflammation of the lining of the nose and paranasal sinuses.
It is characterised by nasal obstruction, rhinorrhoea (anterior or
posterior nasal discharge), facial discomfort and often a reduction
in the sense of smell, which last for more than 12 weeks (Fokkens
2007; Scadding 2008). There are limited data on the prevalence of
chronic rhinosinusitis in the general population, but estimates vary
between 2% and 16% in Europe and the United States (Bachert
2009; Fokkens 2007). In the 2003 US National Health Survey,
nearly 30 million CRS sufferers were identified (Wallace 2008).
The annual treatment costs of chronic rhinosinusitis are estimated
to be in the billions and this is likely to underestimate indirect costs
from reduced work performance, sickness absenteeism and lost
days from work (Ray 1999; Fokkens 2007). Patients with chronic
rhinosinusitis have been shown to report significantly lower qual-
ity of life scores than those patients with congestive heart failure,
angina, chronic obstructive pulmonary disease or chronic back
pain (Gliklich 1995).
Of note, 5% to 8% of patients with chronic rhinosinusitis and
nasal polyps will be intolerant to aspirin (acetylsalicylic acid) and
non-steroidal anti-inflammatory drugs (NSAIDs) and almost in-
variably have associated asthma. This triumvirate of disorders is
often referred to as the ’aspirin triad’ or ’Samter’s triad’ (Samter
1968). It is known by several acronyms and names such as aspirin-
induced/intolerant asthma (AIA), aspirin-induced/intolerant rhi-
nosinusitis (AIR), aspirin sensitive asthma (ASA), aspirin hyper-
sensitivity and aspirin exacerbated respiratory disease (AERD).
Hereon, we shall use the term aspirin-induced/intolerant rhinosi-
nusitis (AIR).
Description of the condition
Prevalence and epidemiology
Ameta-analysis showed that the prevalence of aspirin sensitivity in
the general population may be as high as 22% if oral aspirin chal-
lenge tests are used as the diagnostic yardstick instead of patient
history (Jenkins 2004). Moreover, there is almost a 100% cross-
sensitivity to common over-the-counter NSAIDs (Jenkins 2004;
Melillo 2001). Aspirin sensitivity affects about 10% of adults with
chronic asthma and in patients with aspirin sensitivity, 36% to
96% have nasal polyposis as evidenced by endoscopic or radio-
graphic changes (Fokkens 2007).
Aetiopathogenesis
The pathogenetic mechanism of AIR and asthma is complex and
is not fully understood. Common hypotheses include an imbal-
ance in the arachidonic acid pathway causing an overproduction
in leukotrienes in genetically predisposed phenotypes (Jenneck
2007). It is postulated that the inhibition of the COX1 enzyme by
aspirin (or related substances) leads to subsequent inflammatory
cell activation, and the release of both lipid and non-lipid media-
tors (Stevenson 2006). A significantly lower generation of PGE2
and COX2 expression in the nasal and sinus mucosa has been re-
ported (Kowalski 2000; Picado 1999). This could contribute to
the development of the severe eosinophilic inflammation charac-
teristic of AIR patients.
Clinical presentation and diagnosis
AIR usually presents in the third and fourth decades and is more
common in females and in non-atopic individuals (Scadding
2008). It may present initially as non-specific rhinorrhoea and
nasal congestion and progresses over the next decade or so to as-
pirin sensitivity, asthma and nasal polyposis (Szczeklik 2000). The
intolerance/sensitivity canmanifest in a varied fashion and can oc-
cur as any combination of symptoms, ranging from a subtle wors-
ening of rhinorrhoea, hyposmia, post-nasal discharge, congestion,
cough and bronchospasm to, in rare cases, respiratory arrest and
shock. The manifestation within an individual, however, is usu-
ally consistent, with most reactions occurring within 20 to 120
minutes of ingestion of aspirin or a NSAID (Scadding 2008). The
twomost frequent clinical presentations of aspirin hypersensitivity
are aspirin-induced bronchial asthma/rhinosinusitis and aspirin-
induced urticaria/angioedema. They occur only rarely in combi-
nation (Jenneck 2007).
Typically, the presence of aspirin intolerance makes the upper
and lower airways disease severe, persistent and treatment resis-
tant (Fokkens 2007). Patients with AIR have a higher frequency
of hospitalisations and emergency department visits than toler-
ant patients (Berges-Gimeno 2002). Their illness is recalcitrant to
medical and surgical treatment and they are often either steroid
dependant or unresponsive (Scadding 2008). In a pan-European
survey of AIR, inhaled corticosteroids or oral corticosteroids were
used by 80% of afflicted patients with a mean daily dose of 8 mg
of oral prednisolone (Szczeklik 2000). Endoscopic sinus surgery
outcomes are also less successful in AIR patients compared with
aspirin tolerant patients, with more frequent and earlier relapses
(Gosepath 1999).
The diagnosis of aspirin sensitivity relies upon either a clear history
of two or more aspirin/NSAID induced reactions and/or on as-
pirin challenge, which can be oral, inhaled or intranasal (Scadding
2008). Establishing a diagnosis of aspirin intolerance is important.
It provides the patient with a host of common drugs that must be
avoided, diagnoses a particularly severe and recalcitrant form of
disease phenotype and allows a choice of specific therapy such as
leukotriene modifiers or aspirin desensitisation (Fokkens 2007).
Unfortunately, in vitro tests lack sufficient sensitivity and speci-
ficity to diagnose AIR accurately (Scadding 2008). While aspirin
challenge tests are recommended as the investigations of choice,
there is little evidence for the existence of subclinical aspirin sen-
sitivity (Killen 2003) and therefore they cannot be recommended
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as a screening test. The use of provocation testing is primarily
confined to research settings or to patients undergoing desensiti-
sation. Due to the risk of anaphylaxis, provocation testing must be
carried out by trained personnel in facilities with full resuscitation
protocols (Scadding 2008).
Oral aspirin challenge with placebo control is widely used, but is
time consuming (it canbe three days long), andmay provoke severe
bronchospastic and anaphylactoid reactions. Moreover, a negative
oral challenge cannot by itself rule out AIR. Indeed the possibility
of false-negative responses increases when diagnostic provocation
tests with aspirin are carried out in asthmatics being treated with
corticosteroids or during symptom-free intervals (Melillo 2001).
However, when endpoints such as a 20% reduction in forced expi-
ratory volume in 1 second (FEV1), or characteristic extrathoracic
symptoms (such as severe rhinorrhoea and nasal congestion), are
used oral aspirin challenges have a sensitivity of 89% and speci-
ficity of 93% (Nizankowska-Mogilnicka 2007).
Inhalation or nasal challenge with lysine aspirin (L-ASA) is be-
coming the preferred method. L-ASA is more soluble than aspirin
(40% versus 0.3%), is non-irritant, and is well tolerated when in-
haled (Melillo 2001). Nasal challenge with L-ASA is equally sensi-
tive and specific (95.7% and 86.7%, respectively), but a negative
test does not preclude aspirin sensitivity (Nizankowska 2000). Its
negative predictive value is as low as 78.6% and an oral challenge
is recommended after a negative nasal test (Nizankowska 2000).
Lastly, irrespective of challenge results, aspirin sensitivity should
always be suspected in patients with severe nasal polyposis, espe-
cially those with recurrent polyps and steroid dependent refractory
asthma (Scadding 2008).
Description of the intervention
Treatment options
Prevention
Patients should be warned to avoid all drugs with COX-1 inhibitor
activity. Although selective COX-2 inhibitors and paracetamol
appear to be safe, the first dose should preferably be administered in
hospital under monitoring (Scadding 2008). The role of avoiding
preservatives, additives and high salicylate foods is controversial,
with some benefit reported in open studies (Scadding 2008).
Leukotriene pathway modification
There is evidence that leukotriene modifiers like montelukast
ameliorate nasal symptoms, decrease nasal response to an aspirin
challenge and reduce the need for corticosteroids (Lee 2004;
Micheletto 2004; Tohda 2002). In an uncontrolled prospective
study of 678 patients with AIR, leukotriene modifiers alone or in
combination blocked lower respiratory tract reactions rather than
upper respiratory symptoms during aspirin challenge in some pa-
tients. There was no change in the overall rate of positive chal-
lenge results (White 2005). Leukotriene modifiers are only par-
tially effective and patients often experience breakthrough nasal
and bronchospastic symptoms despite treatment (Volkman 2002).
Aspirin desensitisation
Aspirin desensitisation is an important therapeutic option for pa-
tients who have inadequately controlled AIR and/or asthma de-
spite treatment with topical corticosteroids and leukotriene-modi-
fying drugs. Aspirin desensitisation reduces the reactions to aspirin
by repeated and increasing exposure to prudent daily doses until
all reactions cease. Just like provocation testing, desensitisation can
be performed via the oral, endonasal or inhalational routes.
Aspirin desensitisation has been described as a treatment modality
since 1922 (Widal 1987). In 1977, Bianco et al tried the bronchial
provocation test with L-ASA in asthmatic patients intolerant to as-
pirin, and observed the existence of a refractory period post-chal-
lenge (Bianco 1977). At the end of the trial (within 20 days), all pa-
tients tolerated 500 mg of aspirin bymouth. Several author groups
have since reported successful desensitisation with good clinical
efficacy, a low risk-profile and high cost-effectiveness (Gollapudi
2004). There is some evidence that desensitisation may be more
effective for rhinosinusitis symptoms than for lower airway symp-
toms, but overall patient hospitalisations and emergency depart-
ment visits are reduced (Morwood 2005).
A typical oral regime will consist of gradually increasing doses of
oral aspirin, and desensitisation takes a few days to achieve. Dif-
ferent authors have recommended various regimes and dosages
ranging from 100 mg to 1300 mg of oral aspirin so as to maintain
a reduction of polyp size, improvement in olfaction and need for
revision surgery, and improvement in lower airway outcomes (Lee
2007; Kowalski 1986; Rozsasi 2008; Stevenson 1996). The Eu-
ropean Network of Aspirin-Induced Asthma (AIANE) have de-
scribed these procedures used to obtain desensitisation as ’adap-
tive deactivation’ to distinguish them from the desensitisation
obtained by specific immunotherapy in allergic asthma (Melillo
2001). ’Rush deactivation’ is obtained in two days by administer-
ing L-ASA until induction of tolerance. ’Individual dose titration’
is a combination of inhalation and oral administration of aspirin,
and complete tolerance (which means that a single dose of 500
mg of aspirin is safely tolerated) is generally induced in 12 days.
Endonasal desensitisation has also been successfully carried out
using the topical application of L-ASA for the specific treatment
of AIR (Nucera 2000; Patriarca 1991). One author group have
reported a lack of efficacy with a regimen of 16 mg of topical L-
ASA or placebo instilled intranasally every 48 hours for six months
(Parikh 2005). However, the same group reported improvements
in polyp scores, peak nasal inspiratory flow rates and nasal nitric
oxide levels using an endonasal regimen of 30 mg/ml L-ASA to
each side in a dose ramp from 2 mg/day, increased every two
or three days up to a maximum of 54 mg/day (Ogata 2007).
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Endonasal desensitisation may be sensitive to local factors such as
nasal polyp size, mucociliary clearance, or to the concentration or
regime of L-ASA.
Initial desensitisation by any route must be followed by mainte-
nance dosing, as this deactivated state is only sustained for two
to five days after cessation of aspirin. After this, one can ingest
aspirin or NSAIDs on an indefinite basis by taking a maintenance
dose of aspirin without any serious adverse effects in many cases
(Szczeklik 2003). With appropriate monitoring equipment and
adequately trained personnel, this can be done as an outpatient
regimen (Macy 2007). It is important to note that if doses of
aspirin are missed for any reason for more than 48 hours, then
a repeat graded desensitisation will need to be done, or else se-
vere reactions may be provoked. Inpatient desensitisation has been
recommended for patients with the following risk factors: beta-
blocker use, recent myocardial infarction, severe asthma, history
of severe or life threatening aspirin or NSAID reaction, or any
medical condition or drug treatment regimen that wouldmake the
management of severe asthma or anaphylactoid reaction difficult
(Macy 2007). Pre-treatment with a cysteinyl leukotriene modifier
such as montelukast, zileuton (or both) significantly reduces the
incidence and severity of any aspirin-induced bronchospastic re-
actions (White 2005).
With oral and inhaled desensitisation, there is a small but perti-
nent risk of anaphylactoid and bronchospastic reactions. Full car-
diopulmonary resuscitation equipment must be available in the
centre conducting desensitisation, and the patient must be under
the supervision of a practitioner with advanced life-support train-
ing for two to three hours. The risks of desensitisation also in-
clude cutaneous reactions and gastrointestinal symptoms (dyspep-
sia, gastritis or haemorrhage). These are observed in about 20%
of patients treated with aspirin (Fokkens 2007; Morwood 2005).
There should be a protocol for dealing with aspirin-induced reac-
tions; for example, ocular reactions which can be treated with top-
ical antihistamines, gastrointestinal symptoms with proton pump
inhibitors or H2 blockers, urticaria/angioedema with adrenaline
and steroids, and bronchospasm with inhaled beta agonists etc.
(Stevenson 2006). Oral aspirin desensitisation followed by main-
tenance daily dosing may cause significant side effects, including
gastrointestinal bleeding at high doses. There is some evidence to
suggest that oral doses as low as 100 mg daily may be effective for
maintenance therapy and this could potentially circumvent some
of the adverse effects associatedwith currently recommended doses
of 300 mg (Gosepath 1999).
How the intervention might work
While the pathophysiologic mechanisms of desensitisation remain
obscure, a decrease in the number of nasal inflammatory cells ex-
pressing the Cyst-LT1 receptor remains one of the possibilities
(Szczeklik 2006). Peripheral blood monocytes from desensitised
patients synthesise less thromboxane B2, amajor product of COX-
1 and -2 (Szczeklik 2003). Another possibility is that aspirin de-
sensitisation interferes withCyst-LT1 receptors or intracellular sig-
nalling mechanisms in such a way that although leukotrienes are
available, they cannot induce an effector event (Szczeklik 2003).
The precise mechanisms of adaptive deactivation and oral desen-
sitisation with aspirin are still unknown. However, refractoriness
to a bronchospasm inducing stimulus is a phenomenon which is
unique in secondary types of asthma, e.g. exercise-induced asthma.
Similarly, AIR patients also exhibit a refractory period after aspirin
challenge (Picado 2002). During this time further doses do not
lead to a deterioration of their condition.
Why it is important to do this review
Most of the evidence for desensitisation is anecdotal and uncon-
trolled, with varied regimens, routes of administration (oral, en-
donasal) and dosages. It is important to evaluate the efficacy and
safety of aspirin desensitisation in patients with the aspirin triad,
as treatment options for this severely afflicted group are minimal.
Clinical benefits reported in long-term uncontrolled studies in-
clude reduction in nasal obstruction, decreased polyp size, im-
provement in the sense of smell, decreased incidence of respira-
tory and sinus infections, reduced need for nasal corticosteroids,
and a reduction in ’rescue’ systemic steroids and sinus and polyp
surgery episodes (Rozsasi 2008; Stevenson 1996). In particular,
patients with therapy-resistant rhinosinusitis and recurrent nasal
polyps (Jenneck 2007), and those on long-term systemic steroids
might benefit fromdesensitisation. Additional benefits in the form
of cross-tolerance to other NSAIDs may also develop as a result of
treatment (Simon 2004). Benefits of desensitisation might there-
fore also be apparent in patients with concomitant illnesses, such
as coronary artery disease or those requiring NSAIDs for bone
and joint conditions. There were no systematic reviews on aspirin
desensitisation in the literature at the time of writing this protocol.
O B J E C T I V E S
To assess the effectiveness of oral, inhaled or intranasal aspirin de-
sensitisation, as monotherapy or as adjunctive therapy, in adult pa-
tients with aspirin intolerant chronic rhinosinusitis, with or with-
out concomitant asthma.Wewill evaluate subjective and objective
parameters of nasal and lower airway function, quality of life and
adverse event profiles.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised and quasi-randomised controlled trials.
Types of participants
Wewill include adult participants over 16 with a clinical diagnosis
of chronic rhinosinusitis, with or without nasal polyposis, accord-
ing to the EPOS2007guidelines (Fokkens 2007) and aspirin intol-
erance diagnosed by history and/or a positive nasal/bronchial/oral
aspirin challenge (as defined by trialists), with or without asthma.
We will not include studies specifically looking at intolerance to
and desensitisation with NSAIDs alone.
Types of interventions
Any oral/inhaled/endonasal aspirin desensitisation, any dosages,
regimens or frequency.
• Aspirin desensitisation versus no intervention.
• Aspirin desensitisation versus placebo.
• Aspirin desensitisation plus any other topical or systemic
therapies for chronic rhinosinusitis currently in clinical use
versus placebo.
• Aspirin desensitisation versus other topical or systemic
therapies for chronic rhinosinusitis currently in clinical use.
Types of outcome measures
Primary outcomes
1. Validated nasal symptom scores. If standard nasal symptom
scores with the same metric are used then pooling will be
considered appropriate. These data will be treated as continuous.
If different instruments are used, then a composite nasal
symptom score will be derived as a percentage of the maximum
symptom score possible and treatment groups compared.
However, data will be interpreted cautiously in this scenario
(Puhan 2006).
2. Severe or fatal adverse reactions necessitating withdrawal
from study or cessation of treatment. These will include any
bleeding events requiring transfusions or surgery, any
gastrointestinal haemorrhage, severe bronchospasm requiring
oral or intravenous steroids, anaphylaxis requiring epinephrine,
angioedema, hospitalisation for outpatient treatment etc.
Secondary outcomes
1. Number of sinus infections.
2. Number of rescue courses of oral corticosteroids.
3. Number of courses of antibiotics.
4. Number of episodes of sinus surgery or polypectomy.
5. Reduction in medication dosage.
6. Validated quality of life questionnaire scores. If standardised
tools such as SNOT-20, SNOT-22, RSOM-31 or RQLQ are
used, then pooling will be considered for the same instrument.
The data will be treated as continuous. If different instruments
are used, then a composite quality of life score will be derived as
a percentage of the maximum possible score and treatment
groups compared.
7. Change in nasoendoscopic polyp scores.
8. Change in olfaction.
9. Change in paranasal sinus CT scores.
10. Change in objective measures of upper airway patency
including peak nasal inspiratory flow rate, nasal volume
estimated by acoustic rhinometry, nasal airway resistance by
rhinomanometry.
11. Change in nasal nitric oxide.
12. Change in tissue or systemic eosinophilia, eosinophilic
cytokines like IL-5, eotaxin, ECP.
13. Change in lower airway symptoms, spirometry, tidal nitric
oxide and quality of life scores. Symptom scores and quality of
life scores for asthma will be dealt with in a similar fashion to the
upper airway.
Search methods for identification of studies
We will conduct systematic searches for randomised controlled
trials. There will be no language, publication year or publication
status restrictions.Wemay contact original authors for clarification
and further data if trial reports are unclear; and we will arrange
translations of papers where necessary.
Electronic searches
We will search the following bibliographic databases:
• the Cochrane Ear, Nose and Throat Disorders Group Trials
Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, current issue);
• PubMed;
• EMBASE;
• CINAHL;
• AMED;
• ISI Web of Science;
• BIOSIS Previews;
• CAB Abstracts;
• LILACS;
• KoreaMed;
• IndMed;
• PakMediNet;
• China National Knowledge Infrastructure;
• mRCT (the metaRegister of Controlled Trials);
• Google.
Subject strategies for databaseswill bemodelled on the search strat-
egy designed for CENTRAL.Where appropriate, we will combine
subject strategies with adaptations of the highly sensitive search
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strategy designed by the Cochrane Collaboration for identifying
randomised controlled trials and controlled clinical trials (as de-
scribed in The Cochrane Handbook for Systematic Reviews of Inter-
ventions Version 5.0.1, Box 6.4.b. (Handbook 2008)).
CENTRAL search strategy
#1 MeSH descriptor Rhinitis explode all trees with qualifier: DT
#2 MeSH descriptor Rhinitis explode all trees with qualifier: TH
#3 MeSH descriptor Sinusitis explode all trees with qualifier: TH
#4 MeSH descriptor Sinusitis explode all trees with qualifier: DT
#5 rhinosinusitis OR nasosinusitis OR sinusitis OR rhinitis OR
pansinusitis OR ethmoiditis OR ethmoiditis OR sphenoiditis
#6 MeSH descriptor Chronic Disease explode all trees
#7 MeSH descriptor Recurrence explode all trees
#8 chronic OR persis* OR recurren*
#9 (#1 OR #2 OR #3 OR #4 OR #5)
#10 (#6 OR #7 OR #8)
#11 (#9 AND #10)
#12 MeSH descriptor Aspirin explode all trees
#13 Aspirin OR Acetyl* OR Acylpyrin OR Aloxiprimum OR
Colfarit OR Dispril OR Easprin OR Ecotrin OR Endosprin OR
MagnecylORMicristinORPolopirinORPolopirynaOR Solprin
OR Solupsan OR Zorprin
#14 ASA OR AIA OR AERD
#15 (#12 OR #13 OR #14)
#16 (#11 AND #15)
#17 MeSH descriptor Desensitization, Immunologic explode all
trees
#18 MeSH descriptor Respiratory Hypersensitivity explode all
trees with qualifier: DT
#19 MeSH descriptor Respiratory Hypersensitivity explode all
trees with qualifier: TH
#20 (sensitiv* OR desensitiz* OR desensitis* OR hypersensit*)
#21 (#17 OR #18 OR #19 OR #20)
#22 (#16 AND #21)
Searching other resources
Wewill scan reference lists of identified publications for additional
trials and contact authors if necessary. PubMed, TRIPdatabase,
NLH ENT & Audiology Specialist Library and Google will be
searched to retrieve existing systematic reviews possibly relevant
to this systematic review, so that we can scan their reference lists
for additional trials.
Data collection and analysis
Selection of studies
SV and SM will assess the studies to be included independently
to identify studies which meet the criteria outlined above. If there
is disagreement we will resolve this by discussion and in the final
instance by arbitration by BL.
Data extraction and management
We will extract data onto standardised, pre-piloted forms. Where
data are missing or unclear, we will attempt to contact the trial
author(s). Data will be extracted so as to allow an intention-to-
treat analysis.
Assessment of risk of bias in included studies
Wewill evaluate the quality of studies using a ’Risk of bias’ table for
each study. This allows an assessment of each study under six do-
mains: sequence generation, blinding, incomplete outcome data,
allocation concealment, selective outcome reporting and ’other is-
sues’. The first part of the tool is a descriptive entry which sum-
marises each included study and from which judgements of bias
can be made. The second part involves assigning a judgement re-
lating to the risk of bias for that entry. This is achieved by answer-
ing a pre-specified question about the adequacy of the study in
relation to the entry, such that a judgement of ’yes’ indicates low
risk of bias, ’no’ indicates high risk of bias, and ’unclear’ indicates
unclear or unknown risk of bias. The results of this bias assessment
will be displayed as a ’Risk of bias’ summary figure generated by
RevMan 5.0 software (Handbook 2008; RevMan 2008).
Data synthesis
Data will be analysed by the intention-to-treat principle. If data
are comparable and of sufficient quality we will combine to give
a summary measure of effect, otherwise data will be treated as
mentioned above or not be combined. We will perform statistical
analysis using Review Manager 5.0 (RevMan 2008). For dichoto-
mous outcomes we will calculate a relative risk (RR). We will use
a weighted mean difference (WMD) or standardised mean dif-
ference (SMD) for continuous outcomes as appropriate. We will
assess heterogeneity using the Chi2 test and I2 statistic available in
RevMan 5. We will use a fixed-effect model where non-significant
heterogeneity is found between studies. If great heterogeneity in
studies is found then we will use a random-effects model.
If data permit we will conduct the following subgroup analyses:
• CRS without asthma;
• CRS with asthma;
• Previous endoscopic sinus surgery.
We will use study quality in sensitivity analyses.
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